Biobot Surgical Raises $8.52M to Accelerate the Robotic Revolution in Prostate Cancer Treatment

Biobot Surgical, a pioneering force dedicated to revolutionizing robotic-assisted biopsy and treatment for prostate cancer, is thrilled to announce the successful raising of $8,520,000 in new funding. This significant investment underscores our commitment to pushing the boundaries of medical innovation and addressing the unmet global need for precise transperineal procedures. With the backing of this robust financial support, we plan to accelerate the development and broader deployment of our state-of-the-art surgical robot, iSR’obot Mona Lisa—a technology that has already earned distinguished regulatory approvals including the CE mark in Europe, FDA clearance in the US, TGA approval in Australia, and HSA endorsement in Singapore. Beyond expanding our technical capabilities, this funding will empower us to extend clinical trials, refine operational workflows, and fortify partnerships with the world’s most prestigious hospitals, ensuring that our cutting-edge approach to prostate disease management reaches a growing patient population. As the prostate cancer treatment landscape continues to evolve, Biobot Surgical remains steadfast in its mission to deliver the precision that modern urologists demand and the compassionate care that patients deserve. By investing in breakthrough research, optimizing robotic performance, and driving strategic initiatives, we are not merely adapting to change—we are actively shaping the future of prostate cancer treatment. This pivotal moment marks an exciting chapter in our journey toward enhancing patient outcomes, elevating the standard of care, and ultimately transforming the lives of those affected by prostate cancer worldwide.